Dr. Liubov S. Sichel is a leading Ukrainian microbiologist and co-founder, chief scientific officer (CSO), and chief executive officer (CEO) of Stellar Biotics LLC. She is responsible for the development of del-IMMUNE V®, a powerful nutritional supplement containing cell wall fragments from a unique strain of bacteria, L. rhamnosus, one of the most effective microbial cell lysates used to treat a range of conditions in both humans and animals.
With more than 30 years of experience, Dr. Sichel is recognized globally as a thought leader in the microbiology space and has received numerous awards for her research and scientific contributions as a scientist, professor, and government official. Notably, she was awarded a Medal of Honor for her role in the development of genetically engineered human interferon in the USSR.
Dr. Sichel’s research has led to more than 180 peer-reviewed publications and 36 patents. She serves as a scientific and product formulations consultant for the supplement industry, and her strains are used by leading companies in the U.S. nutritional supplement and dairy industries.
In 2000, Dr. Sichel established the first Biotechnology faculty at the National Technical University of Ukraine, and she created the country’s initial Biotechnology Education Program. Between 1996 and 2003, Dr. Sichel led the Department of Science & Technology, Ministry of Education and Science; and the Department of Medicine and Biotechnology, Ministry of Science and Technology.
Dr. Sichel earned a Ph.D. in microbiology from Moscow State University (1980) where her research focused on biotechnology of microbial enzymes, microbial polysaccharides, amino acids, probiotic biotechnology, probiotic cell fragments technology, and other microbial products.
She has presented data and been invited as a podium presenter at international conferences in the United States, Canada, Europe, Australia, New Zealand, China, India, most notably the International Conference and Exhibition on Probiotics & Functional Foods; the Global Biotechnology Congress; and the Probiotics & Prebiotics Congress.
Dr. Sichel continues to conduct advanced research on probiotics strains of lactic acid bacteria, their metabolites, and structural composition for developing advanced microbial and biotherapeutic formulations for human and animal use. Currently, Dr. Sichel is leading research studies to support the development of new formulations that combine del-IMMUNE V with other recognized and innovative therapeutics.